• IN8bio entered an at-the-market equity distribution agreement with JonesTrading for sales of common stock from time to time.
• Sales, if any, will be made under its existing Form S-3 shelf registration statement.
• JonesTrading will receive a 3% commission on gross proceeds from shares sold under the program.
• IN8bio has no obligation to sell shares under the agreement.
• Either party can terminate with 10 days’ written notice; the agent can also terminate immediately under specified events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-249684), on June 01, 2026, and is solely responsible for the information contained therein.